DOCSLIB.ORG

United States Patent 19 11 Patent Number: 5,446,070 Mantelle (45) Date of Patent: "Aug

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
United States Patent 19 11 Patent Number: 5,446,070 Mantelle (45) Date of Patent: USOO544607OA United States Patent 19 11 Patent Number: 5,446,070 Mantelle (45) Date of Patent: "Aug. 29, 1995 54 COMPOST ONS AND METHODS FOR 4,659,714 4/1987 Watt-Smith ......................... 514/260 TOPCAL ADMNSTRATION OF 4,675,009 6/1987 Hymes .......... ... 604/304 PHARMACEUTICALLY ACTIVE AGENTS 4,695,465 9/1987 Kigasawa .............................. 424/19 4,748,022 5/1988 Busciglio. ... 424/195 75 Inventor: Juan A. Mantelle, Miami, Fla. 4,765,983 8/1988 Takayanagi. ... 424/434 4,789,667 12/1988 Makino ............ ... 514/16 73) Assignee: Nover Pharmaceuticals, Inc., Miami, 4,867,970 9/1989 Newsham et al. ... 424/435 Fla. 4,888,354 12/1989 Chang .............. ... 514/424 4,894,232 1/1990 Reul ............. ... 424/439 * Notice: The portion of the term of this patent 4,900,552 2/1990 Sanvordeker .... ... 424/422 subsequent to Aug. 10, 2010 has been 4,900,554 2/1990 Yanagibashi. ... 424/448 disclaimed. 4,937,078 6/1990 Mezei........... ... 424/450 Appl. No.: 112,330 4,940,587 7/1990 Jenkins ..... ... 424/480 21 4,981,875 l/1991 Leusner ... ... 514/774 22 Filed: Aug. 27, 1993 5,023,082 6/1991 Friedman . ... 424/426 5,234,957 8/1993 Mantelle ........................... 514/772.6 Related U.S. Application Data FOREIGN PATENT DOCUMENTS 63 Continuation-in-part of PCT/US92/01730, Feb. 27, 0002425 6/1979 European Pat. Off. 1992, which is a continuation-in-part of Ser. No. 0139127 5/1985 European Pat. Off. 813,196, Dec. 23, 1991, Pat. No. 5,234,957, which is a 0159168 10/1985 European Pat. Off. continuation-in-part of Ser. No. 661,827, Feb. 27, 1991, 250187 6/1987 European Pat. Off. abandoned. 0331392 2/1989 European Pat. Off. 51 Int. Cl. ............ - A - P - d - d - - - - - - - - - - - - - - - - - - - - - - - - - A61K 47/32 363224 10/1989 European Pat. Off. U.S. C. ............ 217989 3/1983 Germany . 52 a a is a 8 88.8 s 514/772.6; 424/485; 52460 11/1966 Luxembourg. 424/486; 424/487; 424/488; 514/781; 514/782 352.239 12/1972 Sweden . 58 Field of Search - A - a 424/435, 443, 447, 449, 1360820 7/1974 United Kingdom. 424/450, 484, 485, 486, 487, 488; 514/772.6, 89/10740 11/1989 WIPO . 818, 947, 781, 782 OTHER PUBLICATIONS 56 References Cited U.S. PATENT DOCUMENTS J. F. Butterworth, et al., “Molecular Mechanisms of Local Anesthesia: A Review', Anesthesiology 2,142,537 1/1939 Tisza ..................................... 167/52 72:711–754, 1990. Pertinent pp. 720-721. 2,277,038 3/1942 Curtis .................................... 167/52 2,352,691 7/1944 Curtis .................................. 260/472 Primary Examiner-Thurman K. Page 2,501,544 3/1950 Shrontz ............................... 128/268 Assistant Examiner-Carlos Azpuru 3,249,109 5/1966 Maeth .... ... 28/268 Attorney, Agent, or Firm-Foley & Lardner 3,632,740 1/1972 Robinson .............................. 424/28 3,640,741 2/1972 Etes ........... ... 106/170 57 ABSTRACT 3,814,095 6/1974 Lubens ................................ 128/260 3,972,995 8/1976 Tsuk ..................................... 424/28 Compositions for topical application comprising a ther 4,302.465 11/1981 Ekenstam .. ... 424/267 apeutically effective amount of a pharmaceutical 4,307,075 12/1981 Martin ................................... 424/28 agent(s), a pharmaceutically acceptable carrier, and a 4,466,973 8/984 Rennie ...... ... 424/267 solvent for the pharmaceutical agent(s) in the carrier 4,529,601 7/1985 Broberg ... 514/626 4,572,832 2/986 Kigasawa .............................. 424/19 and methods of administering the pharmaceutical 4,608,249 8/1986 Otsuka .................................. 424/28 agents to a mammal are disclosed. 4,615,697 10/1986 Robinson ...... ... 604/890 4,652,060 12/1986 Broberg ................................ 424/28 45 Claims, No Drawings 5,446,070 1. 2 able to have the anesthetic agent present in a high con COMPOSITIONS AND METHODS FOR TOPICAL centration to effect a rapid onset and, additionally or ADMNSTRATION OF PHARMACEUTICALLY alternatively, in excess of the amount that can be imme ACTIVE AGENTS diately absorbed through the dermis at the site of appli cation, so as to prolong anesthesia. On the other hand, CROSS-REFERENCE TO RELATED the presence of the anesthetic agent primarily in crystal APPLICATIONS line form may irritate sensitive tissues such as mucosal This application is a continuation-in-part of tissues. This is particularly true with regard to lido PCT/US92/01730, filed Feb. 27, 1992, which is a con caine. tinuation-in-part application of U.S. patent application 10 A number of references disclose local anesthetic com Ser. No. 07/813,196, filed Dec. 23, 1991, now issued as positions. For instance, Swedish Patent Publication No. U.S. Pat. No. 5,234,957, which is a continuation-in-part 352,239 published Dec. 27, 1972 in the name of S. G. of U.S. patent application Ser. No. 07/661,827 filed Feb. Davis et al., assigned to Astra Pharmaceutical Products, 27, 1991 and now abandoned, all of which applications Inc., and based on Swedish patent application No. are hereby incorporated by reference. 15 1774.4/70 filed Dec. 30, 1970, discloses a local anesthetic film containing up to 50% lidocaine in crystallized, BACKGROUND OF THE INVENTION microdispersed form. In its final form, this composition 1. Field of the Invention lacks a solvent for the anesthetic agent. The preparation The present invention relates to compositions and is prepared by adding a solution of lidocaine in an or methods for the topical administration of pharmaceuti 20 ganic solvent or an acid addition salt in water, under cally active agents to a mammal in need thereof. More heat and agitation, to a solution or suspension of a film particularly, the present invention relates to anesthesia forming material, namely carboxymethyl cellulose, pol and local anesthetic agents for topical administration. yvinyl alcohol, or a mixture of polyvinyl alcohol and Still more particularly, the invention relates to a method polyvinyl pyrrolidone in water, followed by heating to for the topical administration of an anesthetic agent or a 25 remove any solvent present. combination of anesthetic agents to prevent or amelio U.S. Pat. No. 4,937,078 to Mezei, et al. describes a rate pain. liposome encapsulated local anesthetic or analgesic There is no limitation on the type of pharmaceutical agent that can be used in the present invention, pro agent that is said to provide, when applied to the skin or vided that it can be absorbed topically, typically percu 30 mucous membrane, greater local anesthesia and analge taneously. Thus, the pharmaceutical agent includes sia than the same agents incorporated in conventional both drugs that are topically applied for local effects vehicles such as ointments, creams, or lotions. These and those which can be administered topically for sys liposomal films are preferably applied under occlusion. temic effects. U.S. Pat. Nos. 4,572,832 and 4,695,465 to Kigasawa 2. Description of Background Art 35 and 3,249,109 to Maeth all describe the use of water Anesthetic agents are pharmacologically active soluble protein based systems which incorporate anes agents that block nerve conduction when applied in thetics, and which also contain a tackifier and a poly therapeutically effective amounts. They can be used for hydric alcohol solvent. In the compositions of these local or systemic application. Anesthetic agents have references, the water soluble protein gives the base its been used extensively in the medical field to obtain consistency and bulk and serves as an essential vehicle topical anesthesia. The term "topical” or "topically” is for the incorporation of medicaments and therapeutic used here in its coventional sense as referring to a spot, agents. which can be in or on any part of the body, including U.S. Pat. No. 4,894,232 to Reil, et al. discloses a base but not limited to the epidermis, any other dermis, or for mucosal or denture adhesive pastes and a process for any other body tissue. Topical administration or appli 45 the preparation thereof. Lidocaine is one possible thera cation means the direct contact of the anesthetic with peutic agent suitable for this paste. tissue, such as skin or membrane, particularly the oral or U.S. Pat. No. 3,814,095 to Lubens describes an absor buccal mucosa. Topical administration also includes bent pad for topical application of an anesthetic agent application to hardened tissue such as teeth and append and having a peripheral adhesive. ages of the skin such as nails and hair. Previous methods 50 It is also known to combine two local anesthetic free of applying topical anesthetic agents to the skin or mu bases with different melting points. By mixing the two cosa have used "non-finite' or liquid or semi-liquid anesthetic bases, an eutectic mixture has been reported carriers such as gels, lotions, emulsions, creams, plas that is liquid at room temperature, making it possible to ters, or ointments, or "finite' carriers, non-spreading attain higher concentrations of the active bases. substances which retain their form, e.g. patches, dress 55 U.S. Pat. No. 4,888,354 by Chang relates to a combi ings and bandages. nation of the free base and an acid addition salt of a Local anesthetics generally are esters or amides of variety of drugs, typically in a liquid carrier, to increase benzoic acid derivatives, administered either as the free skin penetration rates. Anesthetics, along with a list of base or the acid-addition salt. Free bases tend to be other suitable drugs are mentioned. This reference spe irritating at high concentrations. Acid-addition salts cifically teaches that base and acid-addition forms of the have low skin permeability. same drug be used in carrier. To be effective, a topical, local anesthetic should U.S.
Load more

Recommended publications
  • The National Drugs List
    ^ ^ ^ ^ ^[ ^ The National Drugs List Of Syrian Arab Republic Sexth Edition 2006 ! " # "$ % &'() " # * +$, -. / & 0 /+12 3 4" 5 "$ . "$ 67"5,) 0 " /! !2 4? @ % 88 9 3: " # "$ ;+<=2 – G# H H2 I) – 6( – 65 : A B C "5 : , D )* . J!* HK"3 H"$ T ) 4 B K<) +$ LMA N O 3 4P<B &Q / RS ) H< C4VH /430 / 1988 V W* < C A GQ ") 4V / 1000 / C4VH /820 / 2001 V XX K<# C ,V /500 / 1992 V "!X V /946 / 2004 V Z < C V /914 / 2003 V ) < ] +$, [2 / ,) @# @ S%Q2 J"= [ &<\ @ +$ LMA 1 O \ . S X '( ^ & M_ `AB @ &' 3 4" + @ V= 4 )\ " : N " # "$ 6 ) G" 3Q + a C G /<"B d3: C K7 e , fM 4 Q b"$ " < $\ c"7: 5) G . HHH3Q J # Hg ' V"h 6< G* H5 !" # $%" & $' ,* ( )* + 2 ا اوا ادو +% 5 j 2 i1 6 B J' 6<X " 6"[ i2 "$ "< * i3 10 6 i4 11 6! ^ i5 13 6<X "!# * i6 15 7 G!, 6 - k 24"$d dl ?K V *4V h 63[46 ' i8 19 Adl 20 "( 2 i9 20 G Q) 6 i10 20 a 6 m[, 6 i11 21 ?K V $n i12 21 "% * i13 23 b+ 6 i14 23 oe C * i15 24 !, 2 6\ i16 25 C V pq * i17 26 ( S 6) 1, ++ &"r i19 3 +% 27 G 6 ""% i19 28 ^ Ks 2 i20 31 % Ks 2 i21 32 s * i22 35 " " * i23 37 "$ * i24 38 6" i25 39 V t h Gu* v!* 2 i26 39 ( 2 i27 40 B w< Ks 2 i28 40 d C &"r i29 42 "' 6 i30 42 " * i31 42 ":< * i32 5 ./ 0" -33 4 : ANAESTHETICS $ 1 2 -1 :GENERAL ANAESTHETICS AND OXYGEN 4 $1 2 2- ATRACURIUM BESYLATE DROPERIDOL ETHER FENTANYL HALOTHANE ISOFLURANE KETAMINE HCL NITROUS OXIDE OXYGEN PROPOFOL REMIFENTANIL SEVOFLURANE SUFENTANIL THIOPENTAL :LOCAL ANAESTHETICS !67$1 2 -5 AMYLEINE HCL=AMYLOCAINE ARTICAINE BENZOCAINE BUPIVACAINE CINCHOCAINE LIDOCAINE MEPIVACAINE OXETHAZAINE PRAMOXINE PRILOCAINE PREOPERATIVE MEDICATION & SEDATION FOR 9*: ;< " 2 -8 : : SHORT -TERM PROCEDURES ATROPINE DIAZEPAM INJ.
    [Show full text]
  • Specifications of Approved Drug Compound Library
    Annexure-I : Specifications of Approved drug compound library The compounds should be structurally diverse, medicinally active, and cell permeable Compounds should have rich documentation with structure, Target, Activity and IC50 should be known Compounds which are supplied should have been validated by NMR and HPLC to ensure high purity Each compound should be supplied as 10mM solution in DMSO and at least 100µl of each compound should be supplied. Compounds should be supplied in screw capped vial arranged as 96 well plate format.
    [Show full text]
  • Lindane Lotion USP, 1% RX Only WARNINGS
    Lindane Lotion USP, 1% RX Only WARNINGS: Lindane Lotion should only be used in patients who cannot tolerate or have failed first-line treatment with safer medications for the treatment of scabies. (See INDICATIONS AND USAGE.) Neurologic Toxicity Seizures and deaths have been reported following Lindane Lotion use with repeat or prolonged application, but also in rare cases following a single application used according to directions. Lindane lotion should be used with caution for infants, children, the elderly, and individuals with other skin conditions (e.g, atopic dermatitis, psoriasis) and in those who weigh < 110 lbs (50 kg) as they may be at risk of serious neurotoxicity. Contraindications Lindane Lotion is contraindicated in premature infants and individuals with known uncontrolled seizure disorders. Proper Use Instruct patients on the proper use of Lindane Lotion, the amount to apply, how long to leave it on, and avoiding re-treatment. Inform patients that itching occurs after the successful killing of scabies and is not necessarily an indication for re-treatment with Lindane Lotion. (See DOSAGE AND ADMINISTRATION.) DESCRIPTION Lindane Lotion USP, 1%, is an ectoparasiticide and ovicide. In addition to the active ingredient, lindane, it contains glycerol monostearate, cetyl alcohol, stearic acid, trolamine, carrageenan, 2- amino-2-methyl-1-propanol, methylparaben, butylparaben, perfume and water to form a lotion. Lindane is the gamma isomer of 1,2,3,4,5,6-hexachlorocyclohexane having the following structural formula: C6H6Cl6 M.W. 290.83 CLINICAL PHARMACOLOGY Lindane Lotion USP, 1%, is an ectoparasiticide and ovicide effective against Sarcoptes scabiei (scabies). Lindane exerts its parasiticidal action by being directly absorbed into the parasites and 1 their ova.
    [Show full text]
  • Revised Use-Function Classification (2007)
    INTERNATIONAL PROGRAMME ON CHEMICAL SAFETY IPCS INTOX Data Management System (INTOX DMS) Revised Use-Function Classification (2007) The Use-Function Classification is used in two places in the INTOX Data Management System: the Communication Record and the Agent/Product Record. The two records are linked: if there is an agent record for a Centre Agent that is the subject of a call, the appropriate Intended Use-Function can be selected automatically in the Communication Record. The Use-Function Classification is used when generating reports, both standard and customized, and for searching the case and agent databases. In particular, INTOX standard reports use the top level headings of the Intended Use-Functions that were selected for Centre Agents in the Communication Record (e.g. if an agent was classified as an Analgesic for Human Use in the Communication Record, it would be logged as a Pharmaceutical for Human Use in the report). The Use-Function classification is very important for ensuring harmonized data collection. In version 4.4 of the software, 5 new additions were made to the top levels of the classification provided with the system for the classification of organisms (items XIV to XVIII). This is a 'convenience' classification to facilitate searching of the Communications database. A taxonomic classification for organisms is provided within the INTOX DMS Agent Explorer. In May/June 2006 INTOX users were surveyed to find out whether they had made any changes to the Use-Function Classification. These changes were then discussed at the 4th and 5th Meetings of INTOX Users. Version 4.5 of the INTOX DMS includes the revised pesticides classification (shown in full below).
    [Show full text]
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2004/0197411A1 Gao Et Al
    US 2004O197411A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0197411A1 Gao et al. (43) Pub. Date: Oct. 7, 2004 (54) ACCEPTABLY NON-HYGROSCOPIC Related U.S. Application Data FORMULATION INTERMEDIATE COMPRISINGA HYGROSCOPIC DRUG (60) Provisional application No. 60/435,147, filed on Dec. 19, 2002. Provisional application No. 60/435,022, (76) Inventors: Danchen Gao, Chicago, IL (US); Ann filed on Dec. 19, 2002. Provisional application No. M. Czyzewski, Grayslake, IL (US) 60/435,422, filed on Dec. 19, 2002. Correspondence Address: Publication Classification PHARMACIA CORPORATION 7 GLOBAL PATENT DEPARTMENT 8. s - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - Ales POST OFFICE BOX 1027 Oa - 1 - O - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - ST. LOUIS, MO 63006 (US) (57) ABSTRACT A Solid particulate composition is provided comprising a (21) Appl. No.: 10/741,530 hygroscopic and/or deliqueScent drug and at least one non hygroscopic polymer. The drug and the at least one polymer are in intimate association and the composition is acceptably (22) Filed: Dec. 18, 2003 non-hygroscopic. Patent Application Publication Oct. 7, 2004 Sheet 1 of 3 US 2004/0197411A1 FIG. 1 40 Mass Increase (%) 20 -- Compound 1 10 RH (%) Mass Increase (%) O 2O 40 60 80 1 OO 120 140 Time (h) Patent Application Publication Oct. 7, 2004 Sheet 2 of 3 US 2004/0197411A1 MaSS increase (%) O 2O 40 60 80 1 OO 12O 140 Mass Increase (%) O 1 OO 2OO 3OO 400 5 OO Patent Application Publication Oct. 7, 2004 Sheet 3 of 3 US 2004/0197411A1 F.G. 5 Mass Increase (%) O 2O 40 6O 8O 1 OO 12O 140 160 US 2004/O1974 11 A1 Oct.
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2020 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Us Anti-Doping Agency
    2019U.S. ANTI-DOPING AGENCY WALLET CARDEXAMPLES OF PROHIBITED AND PERMITTED SUBSTANCES AND METHODS Effective Jan. 1 – Dec. 31, 2019 CATEGORIES OF SUBSTANCES PROHIBITED AT ALL TIMES (IN AND OUT-OF-COMPETITION) • Non-Approved Substances: investigational drugs and pharmaceuticals with no approval by a governmental regulatory health authority for human therapeutic use. • Anabolic Agents: androstenediol, androstenedione, bolasterone, boldenone, clenbuterol, danazol, desoxymethyltestosterone (madol), dehydrochlormethyltestosterone (DHCMT), Prasterone (dehydroepiandrosterone, DHEA , Intrarosa) and its prohormones, drostanolone, epitestosterone, methasterone, methyl-1-testosterone, methyltestosterone (Covaryx, EEMT, Est Estrogens-methyltest DS, Methitest), nandrolone, oxandrolone, prostanozol, Selective Androgen Receptor Modulators (enobosarm, (ostarine, MK-2866), andarine, LGD-4033, RAD-140). stanozolol, testosterone and its metabolites or isomers (Androgel), THG, tibolone, trenbolone, zeranol, zilpaterol, and similar substances. • Beta-2 Agonists: All selective and non-selective beta-2 agonists, including all optical isomers, are prohibited. Most inhaled beta-2 agonists are prohibited, including arformoterol (Brovana), fenoterol, higenamine (norcoclaurine, Tinospora crispa), indacaterol (Arcapta), levalbuterol (Xopenex), metaproternol (Alupent), orciprenaline, olodaterol (Striverdi), pirbuterol (Maxair), terbutaline (Brethaire), vilanterol (Breo). The only exceptions are albuterol, formoterol, and salmeterol by a metered-dose inhaler when used
    [Show full text]
  • Vaginal Delivery System
    (19) & (11) EP 2 062 568 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 27.05.2009 Bulletin 2009/22 A61K 9/00 (2006.01) (21) Application number: 07397042.8 (22) Date of filing: 22.11.2007 (84) Designated Contracting States: • Hanes, Vladimir AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Tarrytown, NY 10591 (US) HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE • Keinänen, Antti SI SK TR 20540 Turku (FI) Designated Extension States: • Holmberg, Svante AL BA HR MK RS 20900 Turku (FI) • Nikander, Hannu (71) Applicant: Bayer Schering Pharma Oy 21330 Paattinen (FI) 20210 Turku (FI) (74) Representative: Matilainen, Mirja Helena et al (72) Inventors: Oy Jalo Ant-Wuorinen AB, • Talling, Christine Iso Roobertinkatu 4-6 A 20610 Turku (FI) 00120 Helsinki (FI) (54) Vaginal delivery system (57) The present invention is related to an intravag- brane (3) encasing the core, said core and membrane inal delivery system for the controlled release of a pro- essentially consisting of a same or different polymer com- gestogen and an estrogen, comprising additionally a position, wherein at cast one of the cores comprises a therapeutically active or a health-promoting substance progestogen or a mixture of a progestogen and an es- (1) capable of giving and/or enhancing the protection trogen, and another core may comprise an estrogen or against bacterial and fungal infections, and/or enhancing a progestogen, and wherein the membrane or the surface the protection against sexually transmitted diseases. The of the membrane or at least one of the cores comprises delivery system consists of one or more compartments said therapeutically active or a health-promoting sub- (2,4,5), one of each comprising a core (7) and a mem- stance.
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • Transdermal Drug Delivery Device Including An
    (19) TZZ_ZZ¥¥_T (11) EP 1 807 033 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61F 13/02 (2006.01) A61L 15/16 (2006.01) 20.07.2016 Bulletin 2016/29 (86) International application number: (21) Application number: 05815555.7 PCT/US2005/035806 (22) Date of filing: 07.10.2005 (87) International publication number: WO 2006/044206 (27.04.2006 Gazette 2006/17) (54) TRANSDERMAL DRUG DELIVERY DEVICE INCLUDING AN OCCLUSIVE BACKING VORRICHTUNG ZUR TRANSDERMALEN VERABREICHUNG VON ARZNEIMITTELN EINSCHLIESSLICH EINER VERSTOPFUNGSSICHERUNG DISPOSITIF D’ADMINISTRATION TRANSDERMIQUE DE MEDICAMENTS AVEC COUCHE SUPPORT OCCLUSIVE (84) Designated Contracting States: • MANTELLE, Juan AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Miami, FL 33186 (US) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • NGUYEN, Viet SK TR Miami, FL 33176 (US) (30) Priority: 08.10.2004 US 616861 P (74) Representative: Awapatent AB P.O. Box 5117 (43) Date of publication of application: 200 71 Malmö (SE) 18.07.2007 Bulletin 2007/29 (56) References cited: (73) Proprietor: NOVEN PHARMACEUTICALS, INC. WO-A-02/36103 WO-A-97/23205 Miami, FL 33186 (US) WO-A-2005/046600 WO-A-2006/028863 US-A- 4 994 278 US-A- 4 994 278 (72) Inventors: US-A- 5 246 705 US-A- 5 474 783 • KANIOS, David US-A- 5 474 783 US-A1- 2001 051 180 Miami, FL 33196 (US) US-A1- 2002 128 345 US-A1- 2006 034 905 Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations.
    [Show full text]